Cannabinoid drugs are known to affect dopaminergic neurotransmission in the basal ganglia circuitry. In this study, we used in vitro and in vivo techniques to investigate whether cannabinoid agonists and antagonist could affect dopaminergic transmission in the striatum by acting at the dopamine transporter. Incubation of striatal synaptosomes with the cannabinoid agonists WIN55,212-2 or methanandamide decreased dopamine uptake (IC 50 = 2.0 lmol/L and 3.1 lmol/L, respectively). A similar inhibitory effect was observed after application of the inactive WIN55,212-2 isomer, S())WIN55,212-3. The CB 1 antagonist AM251 did not reverse WIN55,212-2 effect but rather mimicked it. WIN55,212-2 and AM251 partially displaced the binding of the cocaine analog [ 3 H]WIN35,428, thus acting as dopamine transporter pseudosubstrates in the high micromolar range. High-speed chronoamperometry measurements showed that WIN55,212-2 (4 mg/kg, i.p.) caused significant release of endogenous dopamine via activation of CB 1 receptors, followed by a reduction of dopamine clearance. This reduction was CB 1 -independent, as it was mimicked by S())WIN55,212-3. Administration of AM251 (1 and 4 mg/kg, i.p.) increased the signal amplitude and reduced the clearance of dopamine pressure ejected into the striatum. These results indicate that both cannabinoid agonists and antagonists inhibit dopamine transporter activity via molecular targets other than CB 1 receptors. Keywords: anandamide, basal ganglia, cannabinoid, chronoamperometry, dopamine transporter, striatum. To date, there is no indication that cannabinoid drugs affect DA transmission by acting directly at DAergic neurons, which is consistent with the absence of CB 1 receptors on these cells (Herkenham et al. 1991). Cannabinoid-induced DA efflux in the striatum (Malone and Taylor 1999) has been attributed to CB 1 -mediated inhibition of GABA release from afferents projecting to the substantia nigra (Miller and Walker 1995;Wallmichrath and Szabo 2002), thus leading to increased firing of DAergic neurons. In addition, CB 1 -dependent and -independent inhibition of glutamate release has been implicated in the modulation of the nigrostriatal pathway (Szabo et al. 2000;Gerdeman and Lovinger 2001 Abbreviations used: DA, dopamine; DAergic, dopaminergic; DAT, dopamine transporter; DMSO, dimethyl sulfoxide; mAEA, methanandamide; NAc, nucleus accumbens; S())WIN, S())WIN55,212-3; T 80 , time required for the signal to decline by 80% of its peak amplitude; WIN, WIN55,212-2.